English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

This study aimed to determine whether telomere length (TL) is a marker of cancer risk or genetic status amongst two cohorts of  BRCA1  and  BRCA2  mutation carriers and controls. The first group was a prospective set of 665 male  BRCA1/2  mutation carriers and controls (mean age 53 years), all healthy at time of enrolment and blood donation, 21 of whom have developed prostate cancer whilst on study. The second group consisted of 283 female  BRCA1/2  mutation carriers and controls (mean age 48 years), half of whom had been diagnosed with breast cancer prior to enrolment. TL was quantified by qPCR from DNA extracted from peripheral blood lymphocytes. Weighted and unweighted Cox regressions and linear regression analyses were used to assess whether TL was associated with  BRCA1/2  mutation status or cancer risk. We found no evidence for association between developing cancer or being a  BRCA1  or  BRCA2  mutation carrier and telomere length. It is the first study investigating TL in a cohort of genetically predisposed males and although TL and  BRCA  status was previously studied in females our results don't support the previous finding of association between hereditary breast cancer and shorter TL.

Telomere Length Shows No Association with BRCA1 and BRCA2 Mutation Status